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ABSTRACT  38 
The current study evaluated three biomarkers [homologous recombination deficiency (HRD), tumor 39 
BRCA1/2 (tBRCA) mutations, and CCNE1 copy number variation (CNV)] in ovarian tumors from patients 40 
enrolled on the SCOTROC4 clinical trial for associations with outcome following carboplatinum 41 
monotherapy. Ovarian tumors (n=250), with high-grade serous (HGSOC) subgroup analysis (n=179), 42 
were classified as HRD positive (HRD score {greater than or equal to}42 or tBRCA mutation) and as 43 
CCNE1 amplification positive (CCNE1 CNV score >2.4). Seventy-four (30%) tumors were HRD positive, 44 
including 34 (14%) with tBRCA mutations. Forty-seven (19%) were CCNE1 amplification positive, all of 45 
which were tBRCA wild-type. HRD and tBRCA, but not CCNE1 amplification, were significantly associated 46 
with CA125 complete response in the entire cohort (HRD, p=0.00015; tBRCA p=0.0096), and the HGSOC 47 
subgroup (HRD, p= 0.0016; tBRCA p=0.032). HRD and lack of CCNE1 amplification were associated with 48 
improved progression free survival (PFS) and overall survival (OS) in the full cohort and HGSOC subgroup 49 
(HRD, p=0.00021; CCNE1 status p=0.038). HRD remained significant for OS and PFS after adjusting for 50 
clinical factors, while CCNE1 status only remained significant for PFS. Patients with HRD positive tumors 51 
had greater PFS and OS benefit from platinum dose intensification than HRD negative tumors (p=0.049 52 
58 and p=0.035, respectively). An alternative exploratory HRD score threshold ({greater than or equal 53 
to}33 or tBRCA mutation) was also significantly associated with both PFS and OS in the HGSOC subset. 54 
 55 
IMPLICATIONS 56 
HRD, tumor BRCA1/2 mutations and absence of CCNE1 amplification are associated with improved 57 
survival of ovarian cancer patients treated with platinum monotherapy and HRD positive patients may 58 
benefit from platinum dose intensification. 59 
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INTRODUCTION 60 
Defects in the homologous recombination (HR) pathway are associated with increased 61 
sensitivity to DNA damaging agents and targeted agents, such as PARP inhibitors, across many cancer 62 
types. The most well studied markers of HR pathway defects are mutations in BRCA1 or BRCA2 63 
(BRCA1/2). For example, previous studies have shown that triple-negative breast cancer (TNBC) tumors 64 
and ovarian cancer tumors with BRCA1/2 mutations show improved sensitivity to platinum based 65 
chemotherapy relative to BRCA1/2 wild-type tumors [1, 2]. Similarly, ovarian cancer tumors with 66 
mutations in BRCA1/2 have shown improved sensitivity to PARP inhibitors [3-5]. However, defects in the 67 
HR pathway are not confined to mutations in BRCA1/2 in ovarian cancer. Studies report HR pathway 68 
defects in as many as 50% of epithelial ovarian cancers, a third of which may be caused by something 69 
other than a mutation in  BRCA1 or BRCA2 [6]. 70 
In order to improve the identification of tumors with HR pathway defects that are likely to 71 
respond to DNA-damaging agents, a three-biomarker measure of homologous recombination deficiency 72 
(HRD) has been developed. The HRD assay quantitates genomic instability in a tumor genome [7] based 73 
on three independent measures of genomic instability: loss of heterozygosity (LOH) [8], telomeric allelic 74 
imbalance (TAI) [9], and large-scale state transition (LST) [10]. Each individual measure has been shown 75 
to be associated with response to platinum-based therapy in either triple negative breast (TNBC) or 76 
ovarian cancer [9-11], and the combined score has been shown to be a better predictor of homologous 77 
recombination deficiency than any of the individual scores [12].  78 
An HRD score threshold of 42 was recently developed in a cohort of breast and ovarian 79 
chemotherapy-naïve tumor samples with known BRCA1/2 deficiency status [13]. This threshold is used 80 
in combination with tumor BRCA1/2 mutation status to differentiate tumors with HR deficiency (HRD 81 
positive; HRD score ≥42 or a tumor BRCA1/2 mutation) from HR non-deficient tumors (HRD negative; 82 
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HRD score < 42 and wild-type BRCA1/2). In an independent cohort, HRD positive was significantly 83 
associated with response to platinum based treatment in TNBC [13].  84 
Copy number amplification of the cell cycle regulator Cyclin E1 (CCNE1) is observed only in 85 
tumors with wild-type BRCA1/2 and has been associated with early primary treatment failure and 86 
reduced patient survival in ovarian cancer [14, 15]. In a recent study, Etemadmoghadam et al. 87 
demonstrated that CCNE1 amplified ovarian tumors require the presence of functional BRCA1 protein, 88 
and may be responsive to the proteasome inhibitor bortezomib [16]. In addition CCNE1 amplified 89 
ovarian xenograft models were observed to be sensitive to a combination of a CDK2 inhibitor and an 90 
AKT1 inhibitor in a high throughput screen [17]. 91 
Here, we evaluated using a predefined analysis plan the association of three molecular 92 
biomarkers (HRD status using an HRD score of ≥42 or tBRCA mutation, BRCA1/2 mutations, and CCNE1 93 
copy number amplification) with clinical outcomes following monotherapy with the DNA damaging 94 
agent carboplatin at primary presentation. This was done in a cohort of tumours from patients enrolled 95 
in the SCOTROC4 phase III trial of Stage IC to IV epithelial ovarian carcinoma, primary fallopian tube 96 
carcinoma, or ovarian-type peritoneal carcinomatosis treated with platinum monotherapy, with or 97 
without dose intensification [18]. Available clinical end-points in this study included CA125 response, 98 
PFS and overall survival (OS). All three biomarkers were assessed for their ability to predict response to 99 
platinum monotherapy, and for their association with patient survival outcomes.  100 
Recently the predictive power of the HRD threshold of ≥42 (5th percentile of HRD scores 101 
observed in BRCA1/2 mutant tumors) was evaluated for the prediction of PFS benefit due to the PARP 102 
inhibitor niraparib in second line platinum sensitive germline BRCA1/2 negative HGSOC [4]. While the 103 
HRD ≥42 threshold was associated with significant niraparib PFS benefit, the patient group falling below 104 
this threshold also received significant, albeit reduced, benefit. These data suggest that a revision of the 105 
threshold might better define the responding patient group. To explore this concept in this study we 106 
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tested an HRD threshold of ≥33 (1st percentile of HRD scores observed in BRCA1/2 mutant tumors) 107 
against CA125 response, PFS, and OS in the HGSOC patient set. 108 
The SCOTROC4 trial was a randomized trial of flat dosing versus intrapatient dose escalation of 109 
single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer [18]. Although the trial 110 
showed that intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe, 111 
it provided no improvement in PFS or OS compared with flat dosing. However, we hypothesized that 112 
HRD positive tumors might gain additional benefit from dose intensification and have explored potential 113 
differences depending on HRD status between patients in the dose escalation and flat dosing arms of 114 
the SCOTROC4 trial. 115 
 116 
METHODS 117 
Patients and Treatment 118 
 SCOTROC4 was a phase III randomized trial that enrolled patients with Stage IC to IV epithelial 119 
ovarian carcinoma, primary fallopian tube carcinoma, or ovarian-type peritoneal carcinomatosis [18]. 120 
Patients were randomized into treatment arms and received 6 cycles of 3 weekly carboplatin either at a 121 
flat dose or with an intrapatient dose escalation. The flow of patients and samples through the study is 122 
described in Supplemental Figure 1. Tumour collection for this study was approved by local Ethics 123 
Committee and informed written consent was obtained from patient. Among patients from SCOTROC4 124 
with epithelial ovarian carcinoma, 250 were included in this study based on patient consent and tumor 125 
sample availability. This includes 120 patients in the arm without dose intensification and 130 patients in 126 
the dose intensification arm. Based on pathological review of tumor slides from all samples and TP53 127 
mutation status, 179 samples were classified as HGSOC. Of 179 patients with HGSOC tumors, 115 were 128 
in the flat dose arm and 64 were in the dose escalation arm.  129 
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Clinical Assessments and Endpoints 130 
 Response to therapy was monitored by CA125 response [19]. CA125 measurements were 131 
carried out at baseline, before each cycle of treatment, and then twice monthly. Patients were followed 132 
up for 2 years every 2 months and then every 3 months. Progression free survival (PFS) was determined 133 
according to RECIST version 1.0 [20].  CT scans were carried out at baseline and after six cycles of 134 
treatment and also carried out if CA125 rose or clinical progression was suspected. PFS was the time 135 
from randomisation until PD or death from any cause (whichever occurred first). 136 
 137 
Molecular Analysis 138 
DNA from patient samples was extracted from three to five 10 micron formalin-fixed paraffin-139 
embedded (FFPE) tissue sections from each available tumor sample after scraping areas with the highest 140 
tumor cell density (Promega Maxwell 16 LEV FFPE Plus kit AS1290, Promega, Madison, WI).  FFPE tissue 141 
was incubated overnight in 20 L Proteinase K and 180 L incubation buffer at 70°C in a shaking heat 142 
block. An additional 20 L Proteinase K was then added, followed by 3 hours digestion at 70°C. 10 L of 143 
RNase A (A1973, Promega, Madison, WI) was added followed by RNA digestion at 37°C for 20 minutes. 144 
Lysis buffer (420 L) was then added, and the samples were loaded into Maxwell cartridges. gDNA was 145 
eluted in 110 L of water. 146 
The DNA analysis approach used here has been previously described [13]. Genome-wide SNP 147 
data was generated using a custom hybridization enrichment panel which targets 54,091 SNPs 148 
distributed across the human genome. TP53, BRCA1 and BRCA2 mutation data were also evaluated in 149 
the context of this study. Details of the methods used for identification of BRCA1 and BRCA2 deficient 150 
tumors are provided in Timms et al [7]. Deleterious and suspected deleterious mutations were included 151 
in the analysis [21, 22]. 152 
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Allelic imbalance profiles were generated to determine the scores for each individual biomarker 153 
component (TAI, LST, LOH) and the combined HRD score is the sum of the individual biomarker scores 154 
[7, 13]. An HRD score threshold of 42 (5th percentile of HRD scores observed in BRCA1/2 deficient 155 
tumors) has been previously developed to identify HR deficient tumors [13].  Tumors are considered HR 156 
deficient (HRD positive) if they have a high HRD score (≥42) or a tumor BRCA1 or BRCA2 (tBRCA) 157 
mutation and HR non-deficient (HRD negative) if they have a low HRD score (<42) and wild-type 158 
BRCA1/2 [13]. In this study we explored whether lowering the threshold from the 5th percentile level of 159 
HRD scores observed in BRCA1/2 deficient tumors (HRD score ≥42) to the 1st percentile (HRD score ≥33) 160 
might better define the responding patient group. In these analyses HRD positive status was defined as 161 
an HRD score either greater than or equal to the exploratory threshold of 33 or a BRCA1/2 mutant with 162 
any HRD score. This exploratory threshold was evaluated in the HGSOC subgroup only. 163 
To identify tumors with CCNE1 copy number amplification, the copy number was averaged for 164 
the 3 SNPs on the HRD SNP assay which surround the CCNE1 locus. The average copy number was then 165 
adjusted by the average copy number across all SNPs of the sample to produce a relative amplification 166 
score Supplementary Figure 2. CCNE1 amplification values of between 0.5 and 2 were considered to be 167 
within the accepted range for tumor sample variability and therefore did not represent CCNE1 168 
amplification. Assuming these non-amplified samples to be log-normally distributed, the derived mean 169 
and standard deviation yielded at 99th percentile gave an amplification value of 2.4. Samples that 170 
exceed a CCNE1 amplification score of 2.4 were designated as  CCNE1 amplification positive. 171 
 172 
Statistical Analysis 173 
 Clinical and molecular variables were evaluated as predictors of CA125 response in terms of 174 
odds ratios (ORs) and Wald confidence intervals (CIs) from logistic regression models.  Associations with 175 
PFS and OS were assessed with hazard ratios from Cox proportional hazards (PH) models; categorical 176 
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variables were also evaluated with Kaplan-Meier (KM) curves and Mantel-Cox Log-Rank tests. P-values 177 
from logistic regression and Cox PH models were based on likelihood ratio tests. P-values are reported 178 
as two-sided unless otherwise noted. 179 
180 
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RESULTS 181 
Study Cohort 182 
Patient demographic and clinical data is shown in Supplementary Table 1. CA125 response was 183 
available for 139 patients, while PFS and OS were available for all patients (N=250). Overall, 74 (30%) of 184 
tumors were HRD positive (≥42), including 34 (14%) with tBRCA mutations, and 47 (19%) were identified 185 
as having amplification of CCNE1 (Supplementary Table 1). CCNE1 amplification was observed only in 186 
tumors without BRCA1/2 mutations, which is consistent with previous reports [14, 15]. CCNE1 187 
amplification was observed more frequently in HRD negative tumors in this cohort (logistic p=1.6×10-4; 188 
OR 5.50, 95% CI 1.89-16.0) compared to HRD positive (≥42). The HGSOC subset included 64 (36%) HRD 189 
positive (≥42) tumors, 29 (16%) of which had tBRCA mutations, and 39 (22%) tumors with CCNE1 190 
amplification. 191 
 192 
Association with Response to Platinum Monotherapy 193 
CA125 response and molecular results were available for 139 tumors from the entire cohort and 194 
113 HGSOC tumors. The distribution of HRD scores stratified by CA125 response category is shown in 195 
Figure 1. HRD (≥42) and tBRCA mutation status were both significantly associated with CA125 complete 196 
response (CR) in the entire cohort (p=0.00015 and p=0.0096, respectively), and in the subgroup of 197 
HGSOC patients (p= 0.0016 and p=0.032, respectively; Supplemental Table 2). In the HGSOC subgroup 198 
the HRD positive rate increases from 37% to 52% when the HRD threshold is reduced from ≥42 to ≥33. 199 
HRD status defined as ≥33 or BRCA1/2 mutant remains statistically significantly associated with CA125 200 
complete response (p = 5.0x10-4) (Supplemental Table 2). A receiver operating curve (ROC) was used to 201 
compare sensitivity and specificity of different thresholds as predictors of CA125 response 202 
(Supplementary Figure 2). CCNE1 amplification was not significantly associated with CA125 response in 203 
either the overall cohort or the HGSOC subgroup (Supplemental Table 2). 204 
  10 
 
In a multivariate logistic regression analysis of CA125 complete response adjusted for clinical 205 
variables (age at surgery, histology, grade, stage, bulk of residual disease after surgery, performance 206 
status), HRD status remained significantly associated with response in the overall cohort (p=3.6x10-4, 207 
Supplemental Table 3). Similarly, HRD status (≥42) retained statistical significance in the HGSOC subset 208 
after adjusting for clinical variables (p=0.0050).  In these multivariable analyses of the overall cohort and 209 
HGSOC subset (Supplementary Table 3), HRD status was the only variable that was significantly 210 
associated with CA125 response. HRD status as defined using the exploratory threshold of ≥33 also 211 
retained statistical significance after adjusting for clinical factors (p = 9.4x10-4) (Supplementary Table 4).  212 
tBRCA was significantly associated with CA125 response in the full cohort (p=0.049), but not the HGSOC 213 
subset after adjusting for clinical factors (Supplemental Table 5). 214 
 215 
Association of HRD, tBRCA and CCNE1 with PFS or OS 216 
 HRD status (≥42) was significantly associated with both improved PFS and OS in the overall 217 
cohort (p=0.014 and p=0.016, respectively) and in the HGSOC subgroup (p=2.1x10-4 and p=0.0011, 218 
respectively; Table 1). The HRD positive rate in the HGSOC subgroup increases from 35.8% to 48.6% for 219 
PFS and OS when the threshold is reduced from ≥42 to ≥33. HRD status remains significantly associated 220 
with both improved PFS and OS in the HGSOC subgroup when the threshold is reduced to ≥33 in both 221 
univariate (p= 1.4x10-4and p= 3.3x10-4, respectively; Table 1) and multivariate (p=3.0x10-6and p=3.1x10-4, 222 
respectively) Cox proportional hazards models (Supplementary Table 6). Improvements in median PFS 223 
and OS were similar to those observed for the pre-specified threshold (Supplementary Figure 3). 224 
 tBRCA mutation status was significantly associated with only PFS in the entire cohort (p=0.034), 225 
and with both PFS and OS in the HGSOC subgroup (p=0.0017 and p=0.022, respectively; Table 1). CCNE1 226 
amplification was significantly associated with both PFS and OS in the overall cohort (0.0011 and 0.015, 227 
respectively) and in the HGSOC subgroup (p=0.038 and 0.043, respectively; Table 1). 228 
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In the overall cohort, significant improvements in median survival were observed for all three 229 
biomarkers (Figure 2). HRD status was associated with a 7 month improvement in PFS (18.9 months for 230 
HR deficient vs 11.6 months for non-deficient) and a 20 month improvement in OS (48.5 months for HR 231 
deficient vs 28.1 months for non-deficient) (Supplementary Table 7). Similarly, tBRCA mutations were 232 
associated with an 8 month improvement in PFS and 18 month improvement in OS. CCNE1 amplification 233 
was associated with a 6 month reduction in PFS and a 27 month reduction in OS. Similar associations 234 
were observed in the HGSOC subset (Figure 3 and Supplementary Table 8). 235 
In multivariate Cox PH analyses including all patients, HRD status remained significantly 236 
associated with both PFS (p=2.1x10-5) and OS (p=0.0012) (Table 2). Clinical variables which were also 237 
significantly associated with outcome were grade (p=0.013 and 0.0064), stage (PFS only, p=0.00014), 238 
and bulk of residual disease after surgery (PFS only, p=0.0049) (Table 2). Age at surgery, histology, and 239 
performance status were not significantly associated with either PFS or OS in this analysis. When 240 
multivariate analysis was restricted to HGSOC, HRD status remained significant for PFS and OS 241 
(p=2.2x10-4 and p=0.0048, respectively). Stage and bulk of residual disease also remained significant in 242 
the HGSOC subset for only PFS (p=0.019 and p=0.0055, respectively) (Table 2). Age at surgery and 243 
performance status were not significantly associated with outcome in this analysis. In multivariable 244 
models restricted to the subset of tBRCA non-mutant patients, HRD status was significantly associated 245 
with PFS (p=0.0023, hazard ratio 0.50, 95% CI 0.31-0.80) and OS (p=0.015; hazard ratio 0.47, 95% CI 246 
0.25-0.91) in the entire cohort (N=216), and in HGSOC patients (N=150; PFS p=0.017, hazard ratio 0.55, 247 
95% CI 0.33-0.92; OS p=0.037, hazard ratio 0.49, 95% CI 0.24-0.99). 248 
CCNE1 amplification was associated with PFS (p=1.8×10-4) in the overall cohort after adjusting 249 
for clinical factors (Table 3). When multivariate analysis was restricted to HGSOC, CCNE1 amplification 250 
remained significant for PFS (p=0.0033, Table 3). tBRCA was associated with PFS in the overall cohort 251 
(p=0.0015) and the HGSOC subcohort (0.0019) after adjusting for clinical factors (Supplemental Table 9). 252 
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In Cox PH analyses of the full cohort adjusted for clinical factors, HRD and CCNE1 amplification, 253 
HRD was associated with both PFS and OS (p=7.3×10-4 and p=0.0052 respectively) while CCNE1 254 
amplification was associated with PFS only (p=0.0087). When the same models were examined in the 255 
HGSOC subset, HRD maintained significant associations with both PFS and OS (p=0.0027 and p=0.019 256 
respectively)  (Supplemental Table 9). 257 
 258 
Association of HRD with Dose Intensification 259 
We hypothesized that the improved outcomes observed for HRD positive tumors were due to 260 
increased platinum sensitivity, and that these tumors might gain additional benefit from dose 261 
intensification. One hundred thirty patients were in the dose intensified arm (42 HRD positive) and 120 262 
patients (32 HRD positive) were in the arm without dose intensification. In subset analyses of both arms 263 
combined, there were no significant differences in PFS rates due to dose intensification in either the  264 
HRD negative (hazard ratio 1.13, 95% CI 0.79–1.62) or HRD positive (hazard ratio 0.62, 95% CI 0.33–1.14) 265 
groups. However, Cox PH analysis of the full cohort stratified by treatment arm suggested that the effect 266 
on PFS of platinum dose intensification was greater in the HRD positive group (one-sided interaction 267 
p=0.049). Similarly, for overall survival there were no significant differences in OS rates in the HRD 268 
negative (hazard ratio 1.54, 95% CI 0.96–2.45) or HRD positive (hazard ratio 0.61, 95% CI 0.25–1.48) 269 
groups, but the effect of dose intensification on overall survival was significantly greater for HRD 270 
positive tumors (one-sided interaction p=0.035). These data support the hypothesis that patients with 271 
HR deficient tumors may benefit from dose intensification by intra-patient carboplatin dose escalation. 272 
273 
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DISCUSSION 274 
The HR deficiency score based on measures of genomic instability and BRCA1/2 mutations are 275 
markers of HR pathway defects and previous studies have demonstrated that these molecular markers 276 
predict response to DNA-damaging agents in some cancer types [1-5, 13-15, 23]. In addition, CCNE1 277 
amplification has been associated with chemotherapy resistance and poor prognosis in HGSOC [14, 15]. 278 
Standard of care for first line treatment of advanced ovarian cancer is carboplatin/paclitaxel 279 
combination therapy. However, the SCOTROC-4 study provided an opportunity to investigate the ability 280 
of these three molecular markers to predict treatment response and outcomes following platinum 281 
monotherapy in a cohort of women with ovarian cancer and in the subset with HGSOC, thus avoiding 282 
potential confounding effects of paclitaxel. HGSOC histotype was based on pathological review of tumor 283 
slides by two gynaecological pathologists and TP53 mutation status.  While we recognize the important 284 
of defining histotype in this heterogeneous disease, some non-high grade serous tumours  285 
(endometrioid and mucinous) can have defective homologous repair as determined by the HRD score 286 
(see Supplementary Table 1). Since, the SCOTROC4 trial was all epithelial ovarian cancer we had a 287 
predetermined analysis plan that would analyse all available tumours and then a high grade serous 288 
subgroup analysis. 289 
A positive relationship was observed between the HRD score and BRCA1/2 mutation status, 290 
which is consistent with previously published data [7, 13, 22]. In addition, CCNE1 amplification was 291 
observed only in tumors without BRCA1/2 mutations, as previously reported [14, 15]. A similar 292 
relationship was observed between low HRD score (<42) and CCNE1 amplification here, suggesting that 293 
CCNE1 amplified tumors may require functional homologous recombination repair or represent 294 
alternative tumour development pathways. 295 
CA125 response data showed significant association with both HRD status and BRCA1/2 296 
mutation status, but not with CCNE1 amplification. In multivariate analysis only HRD status retained 297 
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statistical significance. This result is consistent with previously published observations in both TNBC and 298 
ovarian cancer [3-5, 13, 23], and supports the hypothesis that HRD status (as defined by HRD score in 299 
combination with BRCA1/2 mutation screening) predicts sensitivity to DNA damaging agents. 300 
An exploratory analysis of an alternate HRD score threshold at the 1st percentile (≥33) of HRD 301 
scores in BRCA1/2 deficient tumors showed that HRD status remained significantly associated with 302 
CA125 response, while the fraction of biomarker positive to biomarker negative patients increased with 303 
the reduction in the HRD threshold. In a companion diagnostic context, such a threshold adjustment 304 
would enable more patients to receive drug benefit, although will also increase the number of patients 305 
receiving treatment with limited benefit. 306 
HRD and BRCA1/2 mutation status were also significantly associated with improved patient 307 
survival in this study, in both the overall cohort and in the HGSOC subgroup. CCNE1 amplification was 308 
also significantly associated with reduced survival in the overall study cohort, consistent with previous 309 
reports [14, 15]. Both HRD status and CCNE1 amplification remained significantly associated with 310 
outcome in multivariate analysis. 311 
Based on the positive association between HRD status and both response and outcome in this 312 
cohort it was hypothesized that HRD positive tumors would show more benefit from platinum dose 313 
intensification than HRD negative tumors. The effect of dose intensification on PFS and OS was 314 
significantly greater in the HRD positive group, suggesting that patients whose tumours are defective in 315 
HR may benefit from dose escalation based on intrapatient measures of toxicity as in the dose 316 
escalation arm of SCOTROC4 [18]. 317 
HRD status as defined by a  three biomarker HRD score in combination with BRCA1/2 mutation 318 
screening provided significant improvement over clinical variables in identifying patients with ovarian 319 
cancer who had improved response to platinum monotherapy, and was prognostic in this setting. HRD 320 
positive tumors were observed predominantly in HGSOC tumors. In the clinical setting the HRD test 321 
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could be used to identify patients with increased likelihood of response to DNA damaging agents, or 322 
other agents which target the DNA damage repair pathways.  CCNE1 amplification is also prognostic 323 
with patients whose tumors have amplification of this locus having significantly worse outcomes. 324 
Therapies which target this defect may provide an opportunity to improve outcomes for patients with 325 
CCNE1 amplified ovarian tumors. 326 
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Table 1. Univariate Cox PH analysis of PFS and OS for HRD and tBRCA 404 
 405 
  Overall Cohort HGSOC Subset 
Variable Levels 
Hazard Ratio 
(95% CI) 
P-Value 
Hazard Ratio 
(95% CI) 
P-Value 
PFS 
HRD Status (≥42) 
HRD positive 0.65 (0.46-0.93) 
0.014 
0.50 (0.34-0.73) 
0.00021 
HRD negative Ref Ref 
HRD Status (≥33) 
HRD positive ND 
ND 
0.51 (0.36-0.72) 
0.00014 
HRD negative ND Ref 
tBRCA Mutation 
Status 
Mutant 0.61 (0.38-0.99) 
0.034 
0.48 (0.29-0.79) 
0.0017 
Wild-Type Ref Ref 
CCNE1 Amplification 
Status* 
Amplified 1.91 (1.32-2.75) 
0.0011 
1.56 (1.04-2.34) 
0.038 
Not Amplified Ref Ref 
OS 
HRD Status (≥42) 
HRD positive 0.57 (0.36-0.92) 
0.016 
0.45 (0.27-0.74) 
0.0011 
HRD negative Ref Ref 
HRD Status (≥33) 
HRD positive ND 
ND 
0.43 (0.27-0.69) 
0.00033 
HRD negative ND Ref 
tBRCA Mutation 
Status 
Mutant 0.64 (0.35-1.17) 
0.12 
0.50 (0.26-0.95) 
0.022 
Wild-Type Ref Ref 
CCNE1 Amplification 
Status* 
Amplified 1.82 (1.15-2.88) 
0.015 
1.72 (1.04-2.85) 
0.043 
Not Amplified Ref Ref 
*CCNE1 Amplification Status was determined for 248 out of 250 patients in the full cohort, and 178 out 406 
of 179 patients in the HGSOC sub-cohort. 407 
  408 
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Table 2. Multivariate Cox PH analysis of HRD as a predictor of PFS and OS 409 
 410 
   PFS  OS  
Variable Levels 
Patients 
N (%) 
Hazard Ratio 
(95% CI) 
P-Value 
Hazard Ratio 
(95% CI) 
P-Value 
All Patients 
HRD Status HRD positive 71 (31) 0.44 (0.30-0.65) 
2.1×10-5 
0.45 (0.27-0.74) 
0.0012 
HRD negative 155 (69) Ref Ref 
Age at Surgery Years 226 (100) 1.01 (0.99-1.02) 0.55 1.00 (0.98-1.03) 0.68 
Histology Serous*/Clear Cell 189 (84) 1.34 (0.72-2.49) 
0.34 
1.18 (0.53-2.63) 
0.68 
Other 37 (16) Ref Ref 
Grade Low 20 (9) Ref 
0.013 
Ref 
0.0064 
High 206 (91) 2.59 (1.11-6.05) 4.70 (1.13-19.51) 
Stage IC-II 56 (25) Ref 
0.00014 
Ref 
0.12 III 144 (64) 3.33 (1.80-6.16) 1.84 (0.84-4.05) 
IV 26 (12) 2.37 (1.12-4.98) 1.13 (0.42-3.05) 
Bulk of Residual 
Disease 
None/Microscopic 85 (38) Ref 
0.0049 
Ref 
0.091 Macroscopic < 2cm 54 (24) 1.35 (0.80-2.30) 1.41 (0.69-2.86) 
Macroscopic > 2cm 87 (38) 2.04 (1.28-3.24) 1.92 (1.03-3.61) 
Performance 
Status 
0 69 (31) Ref 
0.19 
Ref 
0.17 1 122 (54) 1.17 (0.75-1.84) 1.02 (0.57-1.83) 
2 35 (15) 1.66 (0.94-2.92) 1.73 (0.85-3.56) 
HGSOC 
HRD Status HRD positive 63 (36) 0.46 (0.30-0.70) 
2.2×10-4 
0.47 (0.28-0.81) 
0.0048 
HRD negative 110 (64) Ref Ref 
Age at Surgery Years 173 (100) 1.01 (0.99-1.03) 0.39 1.02 (0.99-1.04) 0.19 
Stage IC-II 31 (18) Ref 
0.019 
Ref 
0.12 III 120 (69) 2.12 (1.07-4.20) 1.59 (0.63-4.00) 
IV 22 (13) 1.28 (0.56-2.90) 0.78 (0.25-2.49) 
Bulk of Residual 
Disease 
None/Microscopic 49 (28) Ref 
0.0055 
Ref 
0.32 Macroscopic < 2cm 48 (28) 1.37 (0.77-2.44) 1.11 (0.52-2.36) 
Macroscopic > 2cm 76 (44) 2.15 (1.28-3.60) 1.54 (0.78-3.03) 
Performance 
Status 
0 41 (24) Ref 
0.083 
Ref 
0.18 1 100 (58) 1.27 (0.75-2.15) 1.13 (0.56-2.30) 
2 32 (18) 1.98 (1.05-3.75) 1.91 (0.83-4.38) 
*One patient with Serous or Endometrioid histology was categorized as Serous for this analysis.  411 
 412 
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Table 3. Multivariate Cox PH analysis of CCNE1 as a predictor of PFS and OS. 413 
 414 
Overall Cohort (N=225) 
  PFS  OS  
Variable Levels 
Hazard Ratio 
(95% CI) 
P-Value 
Hazard Ratio 
(95% CI) 
P-Value 
CCNE1 Status Amplified 2.19 (1.49-3.22) 
1.8×10-4 
1.63 (1.01-2.63) 
0.052 
Not Amplified Ref Ref 
Age at Surgery Years 1.02 (1.00-1.03) 0.051 1.02 (0.99-1.04) 0.15 
Histology Serous*/Clear Cell 1.31 (0.71-2.43) 
0.37 
1.18 (0.53-2.62) 
0.68 
Other Ref Ref 
Grade Low Ref 
0.072 
Ref 
0.020 
High 2.03 (0.87-4.73) 3.89 (0.94-16.1) 
Stage IC-II Ref 
7.9×10-5 
Ref 
0.17 III 3.35 (1.86-6.03) 1.77 (0.83-3.80) 
IV 2.57 (1.25-5.29) 1.17 (0.44-3.08) 
Bulk of Residual 
Disease 
None/Microscopic Ref 
0.0036 
Ref 
0.099 Macroscopic ≤ 2cm 1.10 (0.66-1.83) 1.19 (0.59-2.38) 
Macroscopic > 2cm 1.91 (1.21-3.04) 1.81 (0.96-3.38) 
Performance 
Status 
0 Ref 
0.48 
Ref 
0.28 1 1.06 (0.68-1.65) 0.92 (0.51-1.65) 
2 1.37 (0.78-2.42) 1.45 (0.71-2.99) 
 
HGSOC Subset (N=172) 
  PFS  OS  
Variable Levels 
Hazard Ratio 
(95% CI) 
P-Value 
Hazard Ratio 
(95% CI) 
P-Value 
CCNE1 Status Amplified 1.95 (1.28-2.99) 
0.0033 
1.69 (1.01-2.84) 
0.056 
Not Amplified Ref Ref 
Age at Surgery Years 1.02 (1.00-1.04) 0.019 1.03 (1.00-1.06) 0.018 
Stage IC-II Ref 
0.010 
Ref 
0.13 III 2.45 (1.26-4.75) 1.71 (0.70-4.20) 
IV 1.61 (0.73-3.57) 0.89 (0.29-2.75) 
Bulk of Residual 
Disease 
None/Microscopic Ref 
0.0031 
Ref 
0.25 Macroscopic ≤ 2cm 1.07 (0.61-1.87) 0.94 (0.45-1.97) 
Macroscopic > 2cm 1.99 (1.19-3.30) 1.45 (0.74-2.85) 
Performance 
Status 
0 Ref 
0.29 
Ref 
0.36 1 1.12 (0.67-1.88) 0.99 (0.49-2.01) 
2 1.58 (0.84-2.97) 1.52 (0.66-3.51) 
 415 
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Figure Legends 417 
 418 
Figure 1. Biomarker status and CA125 response 419 
 420 
HRD status, tBRCA mutation status, and CCNE1 amplification as predictors of CA125 response in (A) the 421 
overall cohort (n=137) and (B) the HGSOC subgroup. One BRCA1 mutation carrier is not shown due to 422 
failed HRD score. CR, complete response; PR, partial response; None, no response.  423 
 424 
 425 
 426 
Figure 2. Biomarker status and survival in overall SCOTROC4 cohort 427 
 428 
Kaplan-Meier Survival curves for the overall cohort (N=250) according to (A) HRD status, (B) tBRCA 429 
mutation status, and (C) CCNE1 amplification. PFS, Progression Free Survival,; OS, Overall Survival. 430 
Details of numbers of events and median survival with 95% CI are shown in Supplemental Table 7.  431 
 432 
 433 
Figure 3. Biomarker status and survival in HGSOC SCOTROC4 cohort 434 
 435 
Kaplan-Meier Survival curves for the HGSOC subgroup (N=179) according to (A) HRD status, (B) tBRCA 436 
mutation status, and (C) CCNE1 amplification. PFS, Progression Free Survival,; OS, Overall Survival. 437 
Details of numbers of events and median survival with 95% CI are shown in Supplemental Table 8. 438 
 439 
 440 
 441 
 442 



